Bioteque (4107) Q4 2024 earnings summary

Executive summary

• Consolidated financial statements for the years ended December 31, 2024 and 2023 were audited and present fairly in all material respects in accordance with IFRS and local regulations.

• The business focuses on manufacturing, trading, and selling medical consumables, with global operations and subsidiaries in the Philippines.

Financial highlights

• Operating revenue for 2024 was NT$2,072,575 thousand, up 7% year-over-year from NT$1,944,701 thousand.

• Net income for 2024 was NT$528,260 thousand, a 17% increase from NT$452,550 thousand in 2023.

• Basic EPS for 2024 was NT$7.62, compared to NT$6.53 in 2023.

• Gross margin improved to 44% in 2024 from 42% in 2023.

• Cash and cash equivalents at year-end 2024 were NT$1,236,955 thousand.

Outlook and guidance

• Cash dividend of NT$5.00 per share for 2024 was approved, up from NT$4.50 per share in 2023.

• The Group is evaluating the impact of new IFRS standards effective in future years, with no significant impact expected.